ENOV Enovis Corp

Osaic Holdings Inc. significantly increased its stake in Enovis Corporation (NYSE:ENOV) by 56% in the second quarter, purchasing 50,156 shares to bring its total holdings to 139,727 shares valued at approximately $4.38 million. This acquisition is part of a broader trend of institutional investors raising their positions, with institutions now owning about 98.45% of Enovis stock. Despite a "Moderate Buy" consensus from analysts and a target price of $49.83, the company currently trades around $26.86 with a negative P/E ratio.

Wedge Capital Management L L P NC significantly reduced its stake in Enovis Corporation (NYSE:ENOV) by 68.7% in Q3, selling 111,993 shares and now holding 50,984 shares valued at $1.55 million. Insider activity for Enovis was mixed, with EVP Daniel Pryor selling shares while director John Kleckner increased his holding by 25.1%. Enovis currently has a "Moderate Buy" consensus rating from analysts with an average target price of $49.83.

Assenagon Asset Management S.A. has acquired a new position of 133,319 shares in Enovis Corporation (NYSE:ENOV) during Q3, valued at approximately $4.045 million. Institutional investors now own 98.45% of Enovis, with other large funds also increasing their stakes. Enovis currently has a consensus "Moderate Buy" rating with a target price of $49.83.

Canaccord Genuity has reduced its price target for Enovis Corporation (ENOV) to $50 from $58 while maintaining a Buy rating, based on updated financial estimates. This comes as Freedom Capital initiated coverage with a Buy rating and a $45 price target, highlighting the company's rebound in organic growth and improving competitive position. Enovis recently reported a 9% increase in Q3 2025 net sales, driven by strong performance in its Prevention & Recovery and Reconstructive segments.

Thrivent Financial for Lutherans has significantly reduced its stake in Enovis Corporation, selling 93,804 shares and trimming its holding by 43.9%. Despite this, other institutional investors have mostly increased their positions in ENOV. The stock currently holds a "Moderate Buy" consensus rating from analysts with an average price target of $49.83.

Canaccord Genuity has reduced its price target for Enovis Corporation (ENOV) to $50 from $58 but maintained a Buy rating, updating its model with new 2027 and 2026 estimates. Additionally, Freedom Capital initiated coverage with a Buy rating and a $45 price target, citing expectations for continued organic growth and underappreciated competitive positioning. Enovis's Q3 2025 net sales rose 9% to $549 million, driven by stable end markets and new product momentum.